Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC).

被引：7
|
作者：
Knox, Jennifer J.
Barrios, Carlos H.
Kim, Tae Min
Cosgriff, Thomas
Srimuninnimit, Vichien
Pittman, Kenneth B.
Sabbatini, Roberto
Rha, Sun Young
Flaig, Thomas W.
Page, Ray D.
Beck, J. Thaddeus
Cheung, Foon Yiu
Yadav, Sunil
Patel, Poulam M.
Geoffrois, Lionnel
Schiff, Edward
Niolat, Julie
Berkowitz, Noah
Voi, Maurizio
Motzer, Robert
机构：
[1] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] PUCRS Sch Med, Porto Alegre, RS, Brazil
[3] Seoul Natl Univ Hosp, Jongno Gu, South Korea
[4] East Jefferson Gen Hosp, Crescent City Res Consortium, Metairie, LA USA
[5] Siriraj Hosp, Bangkok, Thailand
[6] Queen Elizabeth Hosp, Woodville, SA 5011, Australia
[7] AOU Policlin Modena, Modena, Italy
[8] Yonsei Univ Coll Med, Seoul, South Korea
[9] Univ Colorado Canc Ctr, Aurora, CO USA
[10] Ctr Canc & Blood Disorders, Ft Worth, TX USA
[11] Highlands Oncol Grp, Fayetteville, AR USA
[12] Queen Elizabeth Hosp, Kowloon, Hong Kong, Peoples R China
[13] Univ Saskatchewan, Saskatoon Canc Ctr, Saskatoon, SK, Canada
[14] Univ Nottingham, Nottingham NG7 2RD, England
[15] Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France
[16] Novartis Pharmaceut, E Hanover, NJ USA
[17] Novartis Pharma SAS, Rueil Malmaison, France
[18] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.4554
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4554
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Phase III Trial to Compare Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab vs Sunitinib Alone in First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma (RCC)
    Motzer, Robert J.
    Grunwald, Viktor
    Hutson, Thomas E.
    Porta, Camillo
    Powles, Thomas
    Eto, Masatoshi
    Dutcus, Corina
    Baig, Mahadi A.
    Dutta, Lea
    Li, Di
    Young, Louise
    Choueiri, Toni K.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 169 - 169
  • [42] A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.
    Motzer, Robert J.
    Grunwald, Viktor
    Hutson, Thomas E.
    Porta, Camillo
    Powles, Thomas
    Eto, Masatoshi
    Dutcus, Corina E.
    Baig, Mahadi Ali
    Dutta, Lea
    Li, Di
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [43] COMPARATIVE EFFICACY OF SUNITINIB VERSUS SORAFENIB AS THE FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Park, S. J.
    Lee, J.
    Park, I.
    Park, K.
    Ahn, J.
    Lee, D. H.
    Song, C.
    Hong, J. H.
    Kim, C.
    Ahn, H.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 287 - 288
  • [44] Comparative Efficacy of Sunitinib versus Sorafenib as First-Line Treatment for Patients with Metastatic Renal Cell Carcinoma
    Park, Seong Joon
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Kwonoh
    Ahn, Yongcheol
    Ahn, Jin-Hee
    Lee, Dae-Ho
    Ahn, Shin
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    [J]. CHEMOTHERAPY, 2012, 58 (06) : 468 - 474
  • [45] A Phase 4 Study of Everolimus to Evaluate Efficacy and Safety in Patients with Metastatic Renal-Cell Carcinoma after Failure of First-Line Sunitinib or Pazopanib (SUNPAZ)
    Schostak, Martin
    de Geeter, Patrick
    Decker, Thomas
    Resch, Anna
    Quiering, Claudia
    Schmitz, Stephan
    [J]. UROLOGIA INTERNATIONALIS, 2020, 104 (3-4) : 263 - 268
  • [46] A population-based study evaluating metastatic renal cell cancer (mRCC) patients treated with interferon (IFN) alone, first-line IFN then second-line sunitinib, or sunitinib alone
    Kollmannsberger, C. K.
    Heng, D. Y.
    Murray, N.
    Chi, K. N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] Quality of life (QOL) with sunitinib versus interferon-alfa (IFN-α) as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): Final results
    Cella, D.
    Michaelson, M. D.
    Cappelleri, J. C.
    Bushmakin, A. G.
    Charbonneau, C.
    Kim, S. T.
    Li, J. Z.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC)
    Motzer, Robert J.
    Grunwald, Viktor
    Hutson, Thomas E.
    Porta, Camillo
    Fowles, Thomas
    Eto, Masatoshi
    Dutcus, Corina E.
    Baig, Mahadi Ali
    Dutta, Lea
    Li, Di
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] Efficacy and safety of first-line sunitinib in Chinese patients with metastatic renal cell carcinoma
    Qin, Shu-Kui
    Jin, Jie
    Guo, Jun
    Wang, Jin-Wan
    Zhou, Fang-Dian
    Huang, Yi-Ran
    Ren, Xiu-Bao
    Ye, Ding-Wei
    Pan, Sharon
    Sajben, Peter
    Wang, Qiao
    [J]. FUTURE ONCOLOGY, 2018, 14 (18) : 1835 - 1845
  • [50] Economic evaluation of sunitinib versus other new targeted therapies as first-line treatment of metastatic renal cell carcinoma (mRCC) in the United States
    Benedict, A.
    Figlin, R. A.
    Charbonneau, C.
    Kreif, N.
    Hariharan, S.
    Negrier, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345